OraSure Technologies(OSUR)

Search documents
OraSure Technologies (OSUR) Q1 Earnings Meet Estimates
Zacks Investment Research· 2024-05-08 23:20
OraSure Technologies (OSUR) came out with quarterly earnings of $0.04 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.37 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this diagnostic test maker would post earnings of $0.13 per share when it actually produced earnings of $0.22, delivering a surprise of 69.23%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.OraSure, whi ...
OraSure Technologies(OSUR) - 2024 Q1 - Quarterly Results
2024-05-08 20:08
Q1 GAAP EPS of $(0.05); Q1 Non-GAAP EPS of $0.04 Restructuring initiatives expected to result in $15 million of annualized expense reductions once fully implemented and position OraSure to achieve cash flow breakeven for core business by end of 2024 EXHIBIT 99.1 Investor Contact: Media Contact: Jason Plagman Amy Koch investorinfo@orasure.com media@orasure.com VP, Investor Relations Director, Corporate Communications OraSure Reports Q1 '24 Revenue of $54.1 Million Delivered initial orders for Syphilis Health ...
OraSure Technologies(OSUR) - 2023 Q4 - Annual Report
2024-03-11 21:12
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________________ FORM 10-K __________________________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to Commission Fil ...
OraSure Technologies(OSUR) - 2023 Q4 - Earnings Call Transcript
2024-02-28 03:16
OraSure Technologies, Inc. (NASDAQ:OSUR) Q4 2023 Earnings Conference Call February 27, 2024 5:00 PM ET Company Participants Jason Plagman - Vice President-Investor Relations Carrie Eglinton Manner - President & Chief Executive Officer Ken McGrath - Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Jacob Johnson - Stephens Matthew Stanton - Jefferies Andrew Cooper - Raymond James Operator Good day, and thank you for standing by. Welcome to the OraSure Technologies Inc. 2023 Fourth ...
OraSure Technologies(OSUR) - 2023 Q4 - Annual Results
2024-02-27 21:10
Investor Contact: Media Contact: Jason Plagman Amy Koch investorinfo@orasure.com media@orasure.com VP, Investor Relations Director, Corporate Communications OraSure Reports Q4 '23 Revenue of $75.9 Million Q4 GAAP EPS of $0.27; Q4 Non-GAAP EPS of $0.22 Grew cash balance to $290.4 million as of December 31, 2023 Enters U.S. Syphilis testing market via strategic distribution agreement with Diagnostics Direct BETHLEHEM, PA, February 27, 2024 (GLOBE NEWSWIRE) – OraSure Technologies, Inc. (NASDAQ: OSUR), a leader ...
OraSure Technologies(OSUR) - 2023 Q3 - Earnings Call Transcript
2023-11-08 00:20
OraSure Technologies, Inc. (NASDAQ:OSUR) Q3 2023 Earnings Conference Call November 7, 2023 5:00 PM ET Company Participants Jason Plagman - Vice President-Investor Relations Carrie Eglinton Manner - President & Chief Executive Officer Ken McGrath - Chief Financial Officer Conference Call Participants Jacob Johnson - Stephens Casey Woodring - JPMorgan Matt Stanton - Jefferies Andrew Cooper - Raymond James Operator Good day, and thank you for standing by. Welcome to the OraSure Technologies Inc 2023 Third Quar ...
OraSure Technologies(OSUR) - 2023 Q3 - Quarterly Report
2023-11-07 22:45
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-Q ______________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023. OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________to _________ . Commission File Number 001-16537 ...
OraSure Technologies(OSUR) - 2023 Q2 - Quarterly Report
2023-08-04 21:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-Q ______________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023. OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________to _________ . Commission File Number 001-16537 _____ ...
OraSure Technologies(OSUR) - 2023 Q2 - Earnings Call Transcript
2023-08-04 03:10
OraSure Technologies, Inc. (NASDAQ:OSUR) Q2 2023 Earnings Conference Call August 3, 2023 5:00 PM ET Company Participants Jason Plagman – Vice President-Investor Relations Carrie Eglinton Manner – President and Chief Executive Officer Ken McGrath – Chief Financial Officer Conference Call Participants Jacob Johnson – Stephens Operator Good day, and thank you for standing by. Welcome to the OraSure Technologies 2023 Second Quarter Earnings Conference Call. At this time all participants are in a listen-only mod ...
OraSure Technologies(OSUR) - 2023 Q1 - Earnings Call Transcript
2023-05-11 02:50
OraSure Technologies, Inc. (NASDAQ:OSUR) Q1 2023 Earnings Conference Call May 10, 2023 5:00 PM ET Company Participants Scott Gleason - Head of Investor Relations Carrie Manner - President & Chief Executive Officer Ken McGrath - Chief Financial Officer Conference Call Participants Casey Woodring - JPMorgan Operator Good day, and thank you for standing-by. Welcome to the OraSure Technologies Earnings Conference Call. At this time, participants are in listen-only mode. After the speaker presentation, there wil ...